Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2007

Conditions
Wet Age-Related Macular Degeneration
Interventions
DRUG

PTK787

Visudyne® + PTK787, 500 mg/day

DRUG

PTK787

Visudyne® + PTK787 1000 mg/day

DRUG

Placebo

Visudyne® + Placebo

Trial Locations (11)

2000

Novartis Investigational Site, Sydney

2145

Novartis Investigative Site, Westmead

2150

Novartis Investigative Site, Parramatta

3002

Novartis Investigative Site, East Melbourne

21287

Wilmer Eye Institute, Baltimore

62701

Springfield Clinic, LLP, Springfield

80210

Porter Adventist Hospital, Eye Lab, Denver

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

33612-4742

USF Eye Institute, Tampa

01960

Lahey Clinic Medical Center, Eye institute, Peabody

05770

Black Hills Regional Eye Institute, Rapid City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY